Press release
Lipodystrophy Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Lipodystrophy Overview
Lipodystrophy syndromes are a heterogeneous group of diseases, characterized by selective absence of adipose tissue. The condition is also characterized by a lack of circulating leptin, which may lead to osteosclerosis. If the fat loss is significant, patients develop insulin resistance and its complications, such as diabetes, dyslipidemia, hepatic steatosis, acanthosis nigrans, polycystic ovarian syndrome, and hypertension.
"Lipodystrophy Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Lipodystrophy Market.
The Lipodystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Lipodystrophy Pipeline Report: https://www.delveinsight.com/report-store/lipodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Lipodystrophy treatment therapies with a considerable amount of success over the years. Lipodystrophy Key players such as - CombiGene, Cell Praxis, Ionis Phrama, Regeneron Pharmaceuticals, Galmed Pharmaceuticals, Zydus Cadila, and others, are developing therapies for the Lipodystrophy treatment
• Lipodystrophy Emerging therapies such as - CGT 2, CT-SCUP, AKCEA-ANGPTL3-LRx, REGN4461, Aramchol, Saroglitazar Magnesium, and others are expected to have a significant impact on the Lipodystrophy market in the coming years.
• In February 2022, Regeneron Pharmaceuticals initiated a randomized double-blind placebo-controlled study of the LEPR Agonist antibody REGN4461 for the treatment of metabolic abnormalities in patients with Familial Partial Lipodystrophy. Two cohorts are being studied based on leptin levels
• In January 2020, Regeneron Pharmaceuticals initiated a randomized, double-blind, placebo-controlled study ofREGN4461, a Leptin Receptor Agonist antibody, in patients with generalized lipodystrophy
• In May 2019, Based on encouraging findings from the international, phase III APPROACH and COMPASS investigations, volanesorsen was licenced for use in Europe to treat adult patients with Familial Chylomicronemia Syndrome (FCS).
Route of Administration
Lipodystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Lipodystrophy Pipeline Therapeutics Assessment
• Lipodystrophy Assessment by Product Type
• Lipodystrophy By Stage and Product Type
• Lipodystrophy Assessment by Route of Administration
• Lipodystrophy By Stage and Route of Administration
• Lipodystrophy Assessment by Molecule Type
• Lipodystrophy by Stage and Molecule Type
DelveInsight's Lipodystrophy Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Some of the key companies in the Lipodystrophy Therapeutics Market include:
Key companies developing therapies for Lipodystrophy are - Regeneron Pharmaceuticals, Ionis Pharmaceuticals, Pfizer, Amunix, Zydus Cadila, Galmed Pharmaceuticals, Cell Praxis, Carmot Therapeutics, CombiGene and others.
Emerging Lipodystrophy Drugs Under Different Phases of Clinical Development Include:
• CGT 2: CombiGene
• CT-SCUP: Cell Praxis
• AKCEA-ANGPTL3-LRx: Ionis
• REGN4461: Regeneron Pharmaceuticals
• Aramchol: Galmed Pharmaceuticals
• Saroglitazar Magnesium: Zydus Cadila
Get a Free Sample PDF Report to know more about Lipodystrophy Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/lipodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Lipodystrophy Pipeline Analysis:
The Lipodystrophy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Lipodystrophy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lipodystrophy Treatment.
• Lipodystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Lipodystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lipodystrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Lipodystrophy product details are provided in the report. Download the Lipodystrophy pipeline report to learn more about the emerging Lipodystrophy therapies at:
https://www.delveinsight.com/sample-request/lipodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Lipodystrophy Pipeline Market Drivers
• Increasing prevalence of HIV is expected to drive growth of the HIV associated lipodystrophy
• Increasing investment for healthcare infrastructure
Lipodystrophy Pipeline Market Barriers
• High cost associated with the treatment
• Lack of awareness among people in developing countries
Scope of Lipodystrophy Pipeline Drug Insight
• Coverage: Global
• Key Lipodystrophy Companies: CombiGene, Cell Praxis, Ionis Phrama, Regeneron Pharmaceuticals, Galmed Pharmaceuticals, Zydus Cadila, and others
• Key Lipodystrophy Therapies: CGT 2, CT-SCUP, AKCEA-ANGPTL3-LRx, REGN4461, Aramchol, Saroglitazar Magnesium, and others
• Lipodystrophy Therapeutic Assessment: Lipodystrophy current marketed and Lipodystrophy emerging therapies
• Lipodystrophy Market Dynamics: Lipodystrophy market drivers and Lipodystrophy market barriers
Request for Sample PDF Report for Lipodystrophy Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/lipodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Lipodystrophy Report Introduction
2 Lipodystrophy Executive Summary
3 Lipodystrophy Overview
4 Lipodystrophy- Analytical Perspective In-depth Commercial Assessment
5 Lipodystrophy Pipeline Therapeutics
6 Lipodystrophy Late Stage Products (Phase II/III)
7 Lipodystrophy Mid Stage Products (Phase II)
8 Lipodystrophy Early Stage Products (Phase I)
9 Lipodystrophy Preclinical Stage Products
10 Lipodystrophy Therapeutics Assessment
11 Lipodystrophy Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Lipodystrophy Key Companies
14 Lipodystrophy Key Products
15 Lipodystrophy Unmet Needs
16 Lipodystrophy Market Drivers and Barriers
17 Lipodystrophy Future Perspectives and Conclusion
18 Lipodystrophy Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Lipodystrophy drugs and therapies- https://www.delveinsight.com/sample-request/lipodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
Lipodystrophy Market https://www.delveinsight.com/report-store/lipodystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Lipodystrophy-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Lipodystrophy Epidemiology https://www.delveinsight.com/report-store/lipodystrophy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Lipodystrophy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Related Reports By DelveInsight -
Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lipodystrophy Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments here
News-ID: 2961798 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Lipodystrophy
Lipodystrophy Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Lipodystrophy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lipodystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Lipodystrophy Research. Learn more about our innovative pipeline…
HIV-Associated Lipodystrophy Treatment Market 2024-2031 | Exclusive Study Report
HIV-Associated Lipodystrophy Treatment Market worth $239.62 Mn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global HIV-Associated Lipodystrophy Treatment Market - (by Lipodystrophy Type (Lipoatrophy and Lipoaccumulation), by Therapeutic class (Anabolism Modulators, Insulin Resistance Modulators, Mitochondrial Antioxidants (l-carnitine), and Other), by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)), Trends, Industry Competition Analysis,…
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of…
HIV Associated Lipodystrophy Syndrome Market 2017-2025 | TMR Research
Global HIV Associated Lipodystrophy Syndrome Market: Snapshot
HIV-associated lipodystrophy is a syndrome that are found in human immune-deficiency virus (HIV)-infected patients who are being administered with active antiretroviral medications for the treatment of HIV infection. Patients have lipohypertrophy, an abnormal central fat accumulation or lipoatrophy, localized loss of fat tissue, or a mixed clinical presentations representing both. The complex morphological signs associated with lipodystrophy syndrome inhibits our understanding of the etiology…
Lipodystrophy Therapeutics- Pipeline Analysis 2018 | Ionis Pharmaceuticals, Inc. …
Lipodystrophy is a rare medical condition which involves problems with fat production, usage, and storage. It is categorized into two types; congenital and acquired lipodystrophy.
Download the sample report @ https://www.pharmaproff.com/request-sample/1077
Congenital lipodystrophies include congenital generalized lipodystrophy, familial partial lipodystrophy, and marfanoid progeroid lipodystrophy syndrome; while acquired lipodystrophy includes acquired partial lipodystrophy, acquired generalized lipodystrophy, centrifugal abdominal lipodystrophy, lipoatrophia annularis, localized lipodystrophy and HIV-associated lipodystrophy.
Get the detailed analysis @ https://www.pharmaproff.com/report/lipodystrophy-therapeutics-pipeline-analysis
The…
HIV-associated Lipodystrophy Market Research Report 2017
Changes in body fat concentration, affecting people with HIV, is known as HIV-associated lipodystrophy. The exact causes of this condition is currently unknown, but research suggests that this disorder can occur either due to HIV infection or as a consequence of side effects associated with drugs used in HIV infection treatment, such as Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Protease Inhibitors (PIs), etc. The lipodystrophy condition is characterized by metabolic abnormalities,…
